RecruitingNot ApplicableNCT06776588

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy


Sponsor

Beidahuang Industry Group General Hospital

Enrollment

200 participants

Start Date

Jan 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

  • Age ≤ 75 years;
  • GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm;
  • Refusing radical surgery or being unable to tolerate surgical treatment;
  • Normal coagulation function, platelet count ≥ 60 × 109 /L;
  • ECOG score ≤ 2 points;

Exclusion Criteria8

  • Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm
  • Platelets \<50×109 /L
  • Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term
  • Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension
  • Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation
  • Patients with severe heart, liver, kidney and brain dysfunction
  • Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term
  • Patients with an estimated survival period of less than 6 months

Interventions

PROCEDUREMicrowave ablation combined with biopsy

CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.


Locations(1)

Beidahuang Industry Group General Hospital

Harbin, Heilongjiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06776588


Related Trials